Skip to main content

Table 1 Patient characteristics

From: Safety of accelerated hypofractionated whole pelvis radiation therapy prior to high dose rate brachytherapy or stereotactic body radiation therapy prostate boost

Age
 Median (IQR) 71 (68–74)
T-Stage (MRI or TRUS)
 1c 1 (5%)
 2a 12 (55%)
 2b 1 (5%)
 2c 3 (14%)
 3a 5 (23%)
Gleason
 3 + 3 1 (5%)
 3 + 4 9 (41%)
 4 + 3 9 (41%)
 4 + 5 1 (5%)
 5 + 4 2 (9%)
Pre-treatment PSA
 Median (IQR) 8.8 (5.8–9.5)
NCCN risk group
 Intermediate risk 13 (59%)
 High risk 7 (32%)
 Very high risk 2 (9%)